EDP-323 is under clinical development by Enanta Pharmaceuticals and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase I drugs for Respiratory Syncytial Virus (RSV) Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EDP-323 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EDP-323 is under development for the treatment of respiratory syncytial viral (RSV) infections. The drug candidate administered through oral route. It acts by targeting RSV L-protein.
Enanta Pharmaceuticals overview
Enanta Pharmaceuticals (Enanta) is a biotechnology company. It discovers and develops small-molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Enanta also develops EDP-938, a potent N-protein inhibitor for the respiratory syncytial virus; and programs to discover and develop chemical entities for the treatment of the hepatitis B virus. The company also develops and markets protease inhibitor compounds for the treatment of the hepatitis C virus through collaborative development and license agreement with AbbVie. Enanta is headquartered in Watertown, Massachusetts, the US
For a complete picture of EDP-323’s drug-specific PTSR and LoA scores, buy the report here.